Clinical Trial

Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Study acronym: DeRIVE
Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 21, 2024 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This phase II trial studies how well daratumumab, ixazomib, and dexamethasone with or without bortezomib work in treating patients with newly diagnosed multiple myeloma. Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as ixazomib, dexamethasone, and bortezomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving daratumumab, ixazomib, and dexamethasone with or without bortezomib may work better in treating patients with multiple myeloma.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT03942224
Lead Sponsor Emory University
Collaborators: Takeda, Janssen, LP, National Institutes of Health (NIH), National Cancer Institute (NCI)
Conditions Plasma Cell Myeloma
Enrollment 49 participants
Start Date 2019-07-03
Primary Completion 2025-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2024-06-21